Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid

NCT02959918 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

152

Enrollment

INDUSTRY

Sponsor class

Conditions

Gout Chronic
Hyperuricemia

Interventions

DRUG: SEL-212
DRUG: SEL-037
DRUG: SVP-rapamycin (SEL-110)

Sponsor

Selecta Biosciences, Inc.